v450 conjugated rat anti mouse ly6c Search Results


anti ly6c viogreen  (Miltenyi Biotec)
94
Miltenyi Biotec anti ly6c viogreen
Anti Ly6c Viogreen, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/v450+conjugated+rat+anti+mouse+ly6c/Ly-6C+Antibody%2C+anti-mouse/pmc07957127-49-18-20
Average 94 stars, based on 1 article reviews
anti ly6c viogreen - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier
v450 conjugated rat anti mouse ly6c  (Bio-Rad)
93
Bio-Rad v450 conjugated rat anti mouse ly6c
FIGURE 6. 4PD-mediated in vivo silencing of STAT3 and C/EBPb restores the efficacy of antitumor vaccines. (A) CT26 tumor–bearing (25 mm2) mice (n = 3) were injected once with 4PD loaded with BrUTP and STAT3 and/or C/EBPb shRNA. At 2, 24, 72, and 120 h postinjection, single-cell suspensions from the tumors were labeled with Abs against CD11b, Ly6G, <t>Ly6C,</t> F4/80, CD206 (to identify gMDSCs, mMDSCs, TAMs, and M1/M2 TAMs), and anti BrU Ab to identify the in vivo–transfected cells (n = 3 mice per group per time point). Data were derived from two independent experiments. The table shows the ANOVA p values comparing the effect of treatment on each population at each time point. (B) CT26 tumor–bearing mice (n = 5 per group) were treated i.v. with 4PD loaded with STAT3- and/or C/EBPb-specific shRNAs. Twenty-four hours after the last injection, T cells were magnetically sorted, CFSE labeled, and tested in MLTCs against CT26. (C, D and E) Starting 9 d after challenge, CT26 tumor–bearing mice were treated i.v. three times a week with PBS or with 4PD loaded with STAT3-specific shRNA, C/EBPb-specific shRNA, or with both shRNAs (20 mg per mouse). At 10 and 17 d after challenge, mice were vaccinated via electroporation with pcDNA3 (D) or with gp70 encoding pcDNA3 (E). Tumor growth was monitored. *p , 0.05 versus control.
V450 Conjugated Rat Anti Mouse Ly6c, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/v450+conjugated+rat+anti+mouse+ly6c/Rat+anti+Mouse+Ly-6C/pm28396317-70-34-61
Average 93 stars, based on 1 article reviews
v450 conjugated rat anti mouse ly6c - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier
v450 rat α-mouse ly6c  (Becton Dickinson)
90
Becton Dickinson v450 rat α-mouse ly6c
FIGURE 6. 4PD-mediated in vivo silencing of STAT3 and C/EBPb restores the efficacy of antitumor vaccines. (A) CT26 tumor–bearing (25 mm2) mice (n = 3) were injected once with 4PD loaded with BrUTP and STAT3 and/or C/EBPb shRNA. At 2, 24, 72, and 120 h postinjection, single-cell suspensions from the tumors were labeled with Abs against CD11b, Ly6G, <t>Ly6C,</t> F4/80, CD206 (to identify gMDSCs, mMDSCs, TAMs, and M1/M2 TAMs), and anti BrU Ab to identify the in vivo–transfected cells (n = 3 mice per group per time point). Data were derived from two independent experiments. The table shows the ANOVA p values comparing the effect of treatment on each population at each time point. (B) CT26 tumor–bearing mice (n = 5 per group) were treated i.v. with 4PD loaded with STAT3- and/or C/EBPb-specific shRNAs. Twenty-four hours after the last injection, T cells were magnetically sorted, CFSE labeled, and tested in MLTCs against CT26. (C, D and E) Starting 9 d after challenge, CT26 tumor–bearing mice were treated i.v. three times a week with PBS or with 4PD loaded with STAT3-specific shRNA, C/EBPb-specific shRNA, or with both shRNAs (20 mg per mouse). At 10 and 17 d after challenge, mice were vaccinated via electroporation with pcDNA3 (D) or with gp70 encoding pcDNA3 (E). Tumor growth was monitored. *p , 0.05 versus control.
V450 Rat α Mouse Ly6c, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/v450+conjugated+rat+anti+mouse+ly6c/fitc/pmc07788822-59-19-25
Average 90 stars, based on 1 article reviews
v450 rat α-mouse ly6c - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
v450 anti-mouse ly6c  (Becton Dickinson)
90
Becton Dickinson v450 anti-mouse ly6c
FIGURE 6. 4PD-mediated in vivo silencing of STAT3 and C/EBPb restores the efficacy of antitumor vaccines. (A) CT26 tumor–bearing (25 mm2) mice (n = 3) were injected once with 4PD loaded with BrUTP and STAT3 and/or C/EBPb shRNA. At 2, 24, 72, and 120 h postinjection, single-cell suspensions from the tumors were labeled with Abs against CD11b, Ly6G, <t>Ly6C,</t> F4/80, CD206 (to identify gMDSCs, mMDSCs, TAMs, and M1/M2 TAMs), and anti BrU Ab to identify the in vivo–transfected cells (n = 3 mice per group per time point). Data were derived from two independent experiments. The table shows the ANOVA p values comparing the effect of treatment on each population at each time point. (B) CT26 tumor–bearing mice (n = 5 per group) were treated i.v. with 4PD loaded with STAT3- and/or C/EBPb-specific shRNAs. Twenty-four hours after the last injection, T cells were magnetically sorted, CFSE labeled, and tested in MLTCs against CT26. (C, D and E) Starting 9 d after challenge, CT26 tumor–bearing mice were treated i.v. three times a week with PBS or with 4PD loaded with STAT3-specific shRNA, C/EBPb-specific shRNA, or with both shRNAs (20 mg per mouse). At 10 and 17 d after challenge, mice were vaccinated via electroporation with pcDNA3 (D) or with gp70 encoding pcDNA3 (E). Tumor growth was monitored. *p , 0.05 versus control.
V450 Anti Mouse Ly6c, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/v450+conjugated+rat+anti+mouse+ly6c/anti+cd19/10__1074_slash_jbc__ra119__008795-185-88-91
Average 90 stars, based on 1 article reviews
v450 anti-mouse ly6c - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
alexa 488 anti-mouse cd31  (Becton Dickinson)
90
Becton Dickinson alexa 488 anti-mouse cd31
FIGURE 6. 4PD-mediated in vivo silencing of STAT3 and C/EBPb restores the efficacy of antitumor vaccines. (A) CT26 tumor–bearing (25 mm2) mice (n = 3) were injected once with 4PD loaded with BrUTP and STAT3 and/or C/EBPb shRNA. At 2, 24, 72, and 120 h postinjection, single-cell suspensions from the tumors were labeled with Abs against CD11b, Ly6G, <t>Ly6C,</t> F4/80, CD206 (to identify gMDSCs, mMDSCs, TAMs, and M1/M2 TAMs), and anti BrU Ab to identify the in vivo–transfected cells (n = 3 mice per group per time point). Data were derived from two independent experiments. The table shows the ANOVA p values comparing the effect of treatment on each population at each time point. (B) CT26 tumor–bearing mice (n = 5 per group) were treated i.v. with 4PD loaded with STAT3- and/or C/EBPb-specific shRNAs. Twenty-four hours after the last injection, T cells were magnetically sorted, CFSE labeled, and tested in MLTCs against CT26. (C, D and E) Starting 9 d after challenge, CT26 tumor–bearing mice were treated i.v. three times a week with PBS or with 4PD loaded with STAT3-specific shRNA, C/EBPb-specific shRNA, or with both shRNAs (20 mg per mouse). At 10 and 17 d after challenge, mice were vaccinated via electroporation with pcDNA3 (D) or with gp70 encoding pcDNA3 (E). Tumor growth was monitored. *p , 0.05 versus control.
Alexa 488 Anti Mouse Cd31, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/v450+conjugated+rat+anti+mouse+ly6c/anti+cd31/pmc05143392-132-33-47
Average 90 stars, based on 1 article reviews
alexa 488 anti-mouse cd31 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
ly-6c  (Becton Dickinson)
90
Becton Dickinson ly-6c
FIGURE 6. 4PD-mediated in vivo silencing of STAT3 and C/EBPb restores the efficacy of antitumor vaccines. (A) CT26 tumor–bearing (25 mm2) mice (n = 3) were injected once with 4PD loaded with BrUTP and STAT3 and/or C/EBPb shRNA. At 2, 24, 72, and 120 h postinjection, single-cell suspensions from the tumors were labeled with Abs against CD11b, Ly6G, <t>Ly6C,</t> F4/80, CD206 (to identify gMDSCs, mMDSCs, TAMs, and M1/M2 TAMs), and anti BrU Ab to identify the in vivo–transfected cells (n = 3 mice per group per time point). Data were derived from two independent experiments. The table shows the ANOVA p values comparing the effect of treatment on each population at each time point. (B) CT26 tumor–bearing mice (n = 5 per group) were treated i.v. with 4PD loaded with STAT3- and/or C/EBPb-specific shRNAs. Twenty-four hours after the last injection, T cells were magnetically sorted, CFSE labeled, and tested in MLTCs against CT26. (C, D and E) Starting 9 d after challenge, CT26 tumor–bearing mice were treated i.v. three times a week with PBS or with 4PD loaded with STAT3-specific shRNA, C/EBPb-specific shRNA, or with both shRNAs (20 mg per mouse). At 10 and 17 d after challenge, mice were vaccinated via electroporation with pcDNA3 (D) or with gp70 encoding pcDNA3 (E). Tumor growth was monitored. *p , 0.05 versus control.
Ly 6c, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/v450+conjugated+rat+anti+mouse+ly6c/ly6g+antibody/pmc06910946__ALL___74___2382___s004-52-12-13
Average 90 stars, based on 1 article reviews
ly-6c - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
pe conjugated anti ly6c  (Cytek Biosciences)
93
Cytek Biosciences pe conjugated anti ly6c
FIGURE 6. 4PD-mediated in vivo silencing of STAT3 and C/EBPb restores the efficacy of antitumor vaccines. (A) CT26 tumor–bearing (25 mm2) mice (n = 3) were injected once with 4PD loaded with BrUTP and STAT3 and/or C/EBPb shRNA. At 2, 24, 72, and 120 h postinjection, single-cell suspensions from the tumors were labeled with Abs against CD11b, Ly6G, <t>Ly6C,</t> F4/80, CD206 (to identify gMDSCs, mMDSCs, TAMs, and M1/M2 TAMs), and anti BrU Ab to identify the in vivo–transfected cells (n = 3 mice per group per time point). Data were derived from two independent experiments. The table shows the ANOVA p values comparing the effect of treatment on each population at each time point. (B) CT26 tumor–bearing mice (n = 5 per group) were treated i.v. with 4PD loaded with STAT3- and/or C/EBPb-specific shRNAs. Twenty-four hours after the last injection, T cells were magnetically sorted, CFSE labeled, and tested in MLTCs against CT26. (C, D and E) Starting 9 d after challenge, CT26 tumor–bearing mice were treated i.v. three times a week with PBS or with 4PD loaded with STAT3-specific shRNA, C/EBPb-specific shRNA, or with both shRNAs (20 mg per mouse). At 10 and 17 d after challenge, mice were vaccinated via electroporation with pcDNA3 (D) or with gp70 encoding pcDNA3 (E). Tumor growth was monitored. *p , 0.05 versus control.
Pe Conjugated Anti Ly6c, supplied by Cytek Biosciences, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/v450+conjugated+rat+anti+mouse+ly6c/PE+Anti-Mouse+Ly-6C/pm26666576-192-46-48
Average 93 stars, based on 1 article reviews
pe conjugated anti ly6c - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier
gr1 apc  (Cytek Biosciences)
92
Cytek Biosciences gr1 apc
FIGURE 6. 4PD-mediated in vivo silencing of STAT3 and C/EBPb restores the efficacy of antitumor vaccines. (A) CT26 tumor–bearing (25 mm2) mice (n = 3) were injected once with 4PD loaded with BrUTP and STAT3 and/or C/EBPb shRNA. At 2, 24, 72, and 120 h postinjection, single-cell suspensions from the tumors were labeled with Abs against CD11b, Ly6G, <t>Ly6C,</t> F4/80, CD206 (to identify gMDSCs, mMDSCs, TAMs, and M1/M2 TAMs), and anti BrU Ab to identify the in vivo–transfected cells (n = 3 mice per group per time point). Data were derived from two independent experiments. The table shows the ANOVA p values comparing the effect of treatment on each population at each time point. (B) CT26 tumor–bearing mice (n = 5 per group) were treated i.v. with 4PD loaded with STAT3- and/or C/EBPb-specific shRNAs. Twenty-four hours after the last injection, T cells were magnetically sorted, CFSE labeled, and tested in MLTCs against CT26. (C, D and E) Starting 9 d after challenge, CT26 tumor–bearing mice were treated i.v. three times a week with PBS or with 4PD loaded with STAT3-specific shRNA, C/EBPb-specific shRNA, or with both shRNAs (20 mg per mouse). At 10 and 17 d after challenge, mice were vaccinated via electroporation with pcDNA3 (D) or with gp70 encoding pcDNA3 (E). Tumor growth was monitored. *p , 0.05 versus control.
Gr1 Apc, supplied by Cytek Biosciences, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/v450+conjugated+rat+anti+mouse+ly6c/APC+Anti-Mouse+Ly-6G%2FLy-6C/pm37941480-248-21-24
Average 92 stars, based on 1 article reviews
gr1 apc - by Bioz Stars, 2026-09
92/100 stars
  Buy from Supplier
horizon™ v450-conjugated anti-lineage cocktail  (Becton Dickinson)
90
Becton Dickinson horizon™ v450-conjugated anti-lineage cocktail
FIGURE 6. 4PD-mediated in vivo silencing of STAT3 and C/EBPb restores the efficacy of antitumor vaccines. (A) CT26 tumor–bearing (25 mm2) mice (n = 3) were injected once with 4PD loaded with BrUTP and STAT3 and/or C/EBPb shRNA. At 2, 24, 72, and 120 h postinjection, single-cell suspensions from the tumors were labeled with Abs against CD11b, Ly6G, <t>Ly6C,</t> F4/80, CD206 (to identify gMDSCs, mMDSCs, TAMs, and M1/M2 TAMs), and anti BrU Ab to identify the in vivo–transfected cells (n = 3 mice per group per time point). Data were derived from two independent experiments. The table shows the ANOVA p values comparing the effect of treatment on each population at each time point. (B) CT26 tumor–bearing mice (n = 5 per group) were treated i.v. with 4PD loaded with STAT3- and/or C/EBPb-specific shRNAs. Twenty-four hours after the last injection, T cells were magnetically sorted, CFSE labeled, and tested in MLTCs against CT26. (C, D and E) Starting 9 d after challenge, CT26 tumor–bearing mice were treated i.v. three times a week with PBS or with 4PD loaded with STAT3-specific shRNA, C/EBPb-specific shRNA, or with both shRNAs (20 mg per mouse). At 10 and 17 d after challenge, mice were vaccinated via electroporation with pcDNA3 (D) or with gp70 encoding pcDNA3 (E). Tumor growth was monitored. *p , 0.05 versus control.
Horizon™ V450 Conjugated Anti Lineage Cocktail, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/v450+conjugated+rat+anti+mouse+ly6c/anti+cd3/pmc07966800-299-5-4
Average 90 stars, based on 1 article reviews
horizon™ v450-conjugated anti-lineage cocktail - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
cd3 epsilon antibody  (NSJ Bioreagents)
99
NSJ Bioreagents cd3 epsilon antibody
FIGURE 6. 4PD-mediated in vivo silencing of STAT3 and C/EBPb restores the efficacy of antitumor vaccines. (A) CT26 tumor–bearing (25 mm2) mice (n = 3) were injected once with 4PD loaded with BrUTP and STAT3 and/or C/EBPb shRNA. At 2, 24, 72, and 120 h postinjection, single-cell suspensions from the tumors were labeled with Abs against CD11b, Ly6G, <t>Ly6C,</t> F4/80, CD206 (to identify gMDSCs, mMDSCs, TAMs, and M1/M2 TAMs), and anti BrU Ab to identify the in vivo–transfected cells (n = 3 mice per group per time point). Data were derived from two independent experiments. The table shows the ANOVA p values comparing the effect of treatment on each population at each time point. (B) CT26 tumor–bearing mice (n = 5 per group) were treated i.v. with 4PD loaded with STAT3- and/or C/EBPb-specific shRNAs. Twenty-four hours after the last injection, T cells were magnetically sorted, CFSE labeled, and tested in MLTCs against CT26. (C, D and E) Starting 9 d after challenge, CT26 tumor–bearing mice were treated i.v. three times a week with PBS or with 4PD loaded with STAT3-specific shRNA, C/EBPb-specific shRNA, or with both shRNAs (20 mg per mouse). At 10 and 17 d after challenge, mice were vaccinated via electroporation with pcDNA3 (D) or with gp70 encoding pcDNA3 (E). Tumor growth was monitored. *p , 0.05 versus control.
Cd3 Epsilon Antibody, supplied by NSJ Bioreagents, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/v450+conjugated+rat+anti+mouse+ly6c/CD3+epsilon+Antibody/custom%40v8271%4026002154
Average 99 stars, based on 1 article reviews
cd3 epsilon antibody - by Bioz Stars, 2026-09
99/100 stars
  Buy from Supplier
gr1 rb6 8c5 biotin  (Cytek Biosciences)
93
Cytek Biosciences gr1 rb6 8c5 biotin
FIGURE 6. 4PD-mediated in vivo silencing of STAT3 and C/EBPb restores the efficacy of antitumor vaccines. (A) CT26 tumor–bearing (25 mm2) mice (n = 3) were injected once with 4PD loaded with BrUTP and STAT3 and/or C/EBPb shRNA. At 2, 24, 72, and 120 h postinjection, single-cell suspensions from the tumors were labeled with Abs against CD11b, Ly6G, <t>Ly6C,</t> F4/80, CD206 (to identify gMDSCs, mMDSCs, TAMs, and M1/M2 TAMs), and anti BrU Ab to identify the in vivo–transfected cells (n = 3 mice per group per time point). Data were derived from two independent experiments. The table shows the ANOVA p values comparing the effect of treatment on each population at each time point. (B) CT26 tumor–bearing mice (n = 5 per group) were treated i.v. with 4PD loaded with STAT3- and/or C/EBPb-specific shRNAs. Twenty-four hours after the last injection, T cells were magnetically sorted, CFSE labeled, and tested in MLTCs against CT26. (C, D and E) Starting 9 d after challenge, CT26 tumor–bearing mice were treated i.v. three times a week with PBS or with 4PD loaded with STAT3-specific shRNA, C/EBPb-specific shRNA, or with both shRNAs (20 mg per mouse). At 10 and 17 d after challenge, mice were vaccinated via electroporation with pcDNA3 (D) or with gp70 encoding pcDNA3 (E). Tumor growth was monitored. *p , 0.05 versus control.
Gr1 Rb6 8c5 Biotin, supplied by Cytek Biosciences, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/v450+conjugated+rat+anti+mouse+ly6c/Biotin+Anti-Mouse+Ly-6G%2FLy-6C/pmc11393282-57-42-59
Average 93 stars, based on 1 article reviews
gr1 rb6 8c5 biotin - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier
cd11b antibody / mac-1  (NSJ Bioreagents)
99
NSJ Bioreagents cd11b antibody / mac-1
FIGURE 6. 4PD-mediated in vivo silencing of STAT3 and C/EBPb restores the efficacy of antitumor vaccines. (A) CT26 tumor–bearing (25 mm2) mice (n = 3) were injected once with 4PD loaded with BrUTP and STAT3 and/or C/EBPb shRNA. At 2, 24, 72, and 120 h postinjection, single-cell suspensions from the tumors were labeled with Abs against CD11b, Ly6G, <t>Ly6C,</t> F4/80, CD206 (to identify gMDSCs, mMDSCs, TAMs, and M1/M2 TAMs), and anti BrU Ab to identify the in vivo–transfected cells (n = 3 mice per group per time point). Data were derived from two independent experiments. The table shows the ANOVA p values comparing the effect of treatment on each population at each time point. (B) CT26 tumor–bearing mice (n = 5 per group) were treated i.v. with 4PD loaded with STAT3- and/or C/EBPb-specific shRNAs. Twenty-four hours after the last injection, T cells were magnetically sorted, CFSE labeled, and tested in MLTCs against CT26. (C, D and E) Starting 9 d after challenge, CT26 tumor–bearing mice were treated i.v. three times a week with PBS or with 4PD loaded with STAT3-specific shRNA, C/EBPb-specific shRNA, or with both shRNAs (20 mg per mouse). At 10 and 17 d after challenge, mice were vaccinated via electroporation with pcDNA3 (D) or with gp70 encoding pcDNA3 (E). Tumor growth was monitored. *p , 0.05 versus control.
Cd11b Antibody / Mac 1, supplied by NSJ Bioreagents, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/v450+conjugated+rat+anti+mouse+ly6c/CD11b+Antibody+%2F+MAC-1/custom%40v2161%4026002154
Average 99 stars, based on 1 article reviews
cd11b antibody / mac-1 - by Bioz Stars, 2026-09
99/100 stars
  Buy from Supplier

Image Search Results


FIGURE 6. 4PD-mediated in vivo silencing of STAT3 and C/EBPb restores the efficacy of antitumor vaccines. (A) CT26 tumor–bearing (25 mm2) mice (n = 3) were injected once with 4PD loaded with BrUTP and STAT3 and/or C/EBPb shRNA. At 2, 24, 72, and 120 h postinjection, single-cell suspensions from the tumors were labeled with Abs against CD11b, Ly6G, Ly6C, F4/80, CD206 (to identify gMDSCs, mMDSCs, TAMs, and M1/M2 TAMs), and anti BrU Ab to identify the in vivo–transfected cells (n = 3 mice per group per time point). Data were derived from two independent experiments. The table shows the ANOVA p values comparing the effect of treatment on each population at each time point. (B) CT26 tumor–bearing mice (n = 5 per group) were treated i.v. with 4PD loaded with STAT3- and/or C/EBPb-specific shRNAs. Twenty-four hours after the last injection, T cells were magnetically sorted, CFSE labeled, and tested in MLTCs against CT26. (C, D and E) Starting 9 d after challenge, CT26 tumor–bearing mice were treated i.v. three times a week with PBS or with 4PD loaded with STAT3-specific shRNA, C/EBPb-specific shRNA, or with both shRNAs (20 mg per mouse). At 10 and 17 d after challenge, mice were vaccinated via electroporation with pcDNA3 (D) or with gp70 encoding pcDNA3 (E). Tumor growth was monitored. *p , 0.05 versus control.

Journal: Journal of immunology (Baltimore, Md. : 1950)

Article Title: 4PD Functionalized Dendrimers: A Flexible Tool for In Vivo Gene Silencing of Tumor-Educated Myeloid Cells.

doi: 10.4049/jimmunol.1600833

Figure Lengend Snippet: FIGURE 6. 4PD-mediated in vivo silencing of STAT3 and C/EBPb restores the efficacy of antitumor vaccines. (A) CT26 tumor–bearing (25 mm2) mice (n = 3) were injected once with 4PD loaded with BrUTP and STAT3 and/or C/EBPb shRNA. At 2, 24, 72, and 120 h postinjection, single-cell suspensions from the tumors were labeled with Abs against CD11b, Ly6G, Ly6C, F4/80, CD206 (to identify gMDSCs, mMDSCs, TAMs, and M1/M2 TAMs), and anti BrU Ab to identify the in vivo–transfected cells (n = 3 mice per group per time point). Data were derived from two independent experiments. The table shows the ANOVA p values comparing the effect of treatment on each population at each time point. (B) CT26 tumor–bearing mice (n = 5 per group) were treated i.v. with 4PD loaded with STAT3- and/or C/EBPb-specific shRNAs. Twenty-four hours after the last injection, T cells were magnetically sorted, CFSE labeled, and tested in MLTCs against CT26. (C, D and E) Starting 9 d after challenge, CT26 tumor–bearing mice were treated i.v. three times a week with PBS or with 4PD loaded with STAT3-specific shRNA, C/EBPb-specific shRNA, or with both shRNAs (20 mg per mouse). At 10 and 17 d after challenge, mice were vaccinated via electroporation with pcDNA3 (D) or with gp70 encoding pcDNA3 (E). Tumor growth was monitored. *p , 0.05 versus control.

Article Snippet: The following Abs were used for flow cytometry analysis: allophycocyaninor Brilliant Violet (BV)711–conjugated rat anti-mouse CD11b (clone M1/70; BD), PerCp-Cy5.5–conjugated rat anti-mouse Ly6G and Ly6C (clone RB68C5; BioLegend), allophycocyanin-Cy7–conjugated rat anti-mouse Ly6G (clone 1-A8), V450-conjugated rat anti-mouse Ly6C (clone AL-21), PEconjugated rat anti-mouse CD124 (clone mIL4R-M1), PE-Cy7–conjugated rat anti-mouse F4/80 (clone BM8; all from BD), FITC-conjugated rat antimouse F4/80 (clone A3-1; AbD Serotec), BV650-conjugated rat anti-mouse CD206 (clone C068C2; BioLegend), PE-Cy7–conjugated hamster antimouse CD11c (clone HL3; BD), eFluor 450–conjugated rat anti-mouse by guest on A pril 13, 2017 http://w w w .jim m unol.org/ D ow nloaded from CD49b (clone DX5; eBioscience), PE-conjugated mouse anti-mouse I-A[d] (clone AMS-32.1), allophycocyanin-conjugated hamster anti-mouse CD80 (clone 16-10A1), FITC-conjugated rat anti-mouse CD86 (clone GL1), allophycocyanin-Cy7–conjugated rat anti-mouse CD4 (clone GK1.5), PEconjugated rat anti-mouse CD25 (clone 3C7), PerCP-conjugated hamster anti-mouse CD3 (clone 145-2C11; all from BD), PerCP–eFluor 710– conjugated rat anti-mouse CD3 (clone 17A2; eBioscience), allophycocyaninCy7–conjugated rat anti-mouse CD19 (clone ID3; BD), allophycocyanin rat anti-mouse Foxp3 (clone FJK-16s; eBioscience), Pacific Blue– or BV711conjugated rat anti-mouse CD8 (clone 53-6.7; BD), allophycocyaninconjugated mouse anti BrdU (clone Bu20a; eBioscience), FITC-conjugated mouse anti-human CD33 (clone HIM3-4), allophycocyanin-H7–conjugated mouse anti-human CD14 (clone MfP9), Pacific Blue–conjugated mouse anti-human CD11b (clone ICRF44; all from BD), allophycocyaninconjugated mouse anti-human IL-4Ra (clone 25463; R&D Systems), and BV711-conjugated mouse anti-human HLA-DR (clone L243; BioLegend). p-STAT6 AF647 Ab (clone J71-773.58.11; BD) was used with Phosflow Perm Buffer IV, as per the manufacturer’s instructions.

Techniques: In Vivo, Vaccines, Injection, shRNA, Labeling, Transfection, Derivative Assay, Electroporation, Control